Positive response to imatinib mesylate therapy for childhood chronic myeloid leukemia
Braz. j. med. biol. res
;
43(6): 580-584, June 2010. ilus
Artigo
em Inglês
| LILACS
| ID: lil-548265
ABSTRACT
Chronic myeloid leukemia (CML) is rare in the pediatric population, accounting for 2-3 percent of childhood leukemia cases, with an annual incidence of one case per million children. The low toxicity profile of imatinib mesylate has led to its approval as a front-line therapy in children for whom interferon treatment has failed or who have relapsed after allogeneic transplantation. We describe the positive responses of 2 children (case 1 - from a 7-year-old male since May 2005; case 2 - from a 5-year-old female since June 2006) with Philadelphia-positive chromosome CML treated with imatinib (300 mg/day, orally) for up to 28 months, as evaluated by morphological, cytogenetic, and molecular approaches. Our patients are alive, are in the chronic phase, and are in continuous morphological complete remission.
Texto completo:
DisponíveL
Índice:
LILACS (Américas)
Assunto principal:
Piperazinas
/
Pirimidinas
/
Leucemia Mielogênica Crônica BCR-ABL Positiva
/
Antineoplásicos
Limite:
Criança
/
Criança, pré-escolar
/
Feminino
/
Humanos
/
Masculino
Idioma:
Inglês
Revista:
Braz. j. med. biol. res
Assunto da revista:
Biologia
/
Medicina
Ano de publicação:
2010
Tipo de documento:
Artigo
País de afiliação:
Brasil
/
Espanha
Instituição/País de afiliação:
Hospital Universitario de Salamanca/ES
/
Universidade Federal do Rio de Janeiro/BR
Similares
MEDLINE
...
LILACS
LIS